A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) (FORTITUDE-ALS)
Researchers are currently recruiting people from QLD, SA and WA who meet the criteria for enrolment in the Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) (FORTITUDE-ALS) (Trial ID NCT03160898). This is a multi-centre Phase 2 clinical trial investigating the safety, tolerability and effectiveness of a drug called reldesemtiv (also known as CK-2127107) in people with MND.